These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1700261)

  • 1. Goserelin--another LH-RH analog for prostate cancer.
    Med Lett Drugs Ther; 1990 Nov; 32(830):102. PubMed ID: 1700261
    [No Abstract]   [Full Text] [Related]  

  • 2. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
    Furr BJ; Hutchinson FG
    Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI; Walker KJ
    Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LH-RH analogue treatment of advanced prostatic cancer.
    Alcini E; D'Addessi A; Vacilotto D
    Prog Clin Biol Res; 1987; 243A():243-4. PubMed ID: 2958854
    [No Abstract]   [Full Text] [Related]  

  • 5. Preliminary report on a phase II multicentric study on depot LH-RH analogue in advanced prostatic cancer.
    Bono AV; Pozzi E; Bianco A; Morelli A; Bolgan A; Albano D; Frugoni A; Usai E
    Prog Clin Biol Res; 1987; 243A():251-3. PubMed ID: 2958856
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of prostatic cancer with monthly injections of an LH-RH analog].
    Svensson M; Varenhorst E; Hjertberg H; Kågedal B; Nordenskjöld B
    Lakartidningen; 1987 Oct; 84(41):3270-1. PubMed ID: 2960863
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
    Kreis W; Budman DR; Delli Bovi P; Vinciguerra V
    Onkologie; 1988 Dec; 11(6):292-3. PubMed ID: 2977219
    [No Abstract]   [Full Text] [Related]  

  • 9. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer].
    Koga H; Naito S
    Nihon Rinsho; 2000 Jul; 58 Suppl():186-90. PubMed ID: 11022711
    [No Abstract]   [Full Text] [Related]  

  • 10. Results obtained in the treatment of prostate cancer patients with Zoladex.
    Williams G; Kerle DJ; Roe SM; Yeo T; Bloom SR
    Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
    [No Abstract]   [Full Text] [Related]  

  • 11. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 12. Zoladex said to be "as effective as surgery" for prostate cancer.
    Oncology (Williston Park); 1990 Feb; 4(2):92-3. PubMed ID: 2143672
    [No Abstract]   [Full Text] [Related]  

  • 13. LHRH-analogues therapy for metastatic prostate cancer.
    Debruyne FM; Fernandez del Moral P; Geboers AD
    Prog Clin Biol Res; 1988; 260():27-39. PubMed ID: 2966406
    [No Abstract]   [Full Text] [Related]  

  • 14. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
    Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
    Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine treatment of prostate cancer.
    Turkes AO; Griffiths K
    Prog Med Chem; 1989; 26():299-321. PubMed ID: 2532376
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoladex treatment of symptomatic prostatic carcinoma.
    Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
    Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of treating advanced prostatic cancer with the LH-RH analogue Zoladex.
    Beacock CJ
    Am J Clin Oncol; 1988; 11 Suppl 2():S115-6. PubMed ID: 2977264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced carcinoma of the prostate by LHRH-agonists.
    Claes HI; Vandenbussche L; Vereecken RL
    Prog Clin Biol Res; 1987; 243A():229-37. PubMed ID: 2958853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.